Efficacy and safety of vildagliptin/pioglitazone combination therapy in Korean patients with diabetes (Q41787191)

9 October 2017

Efficacy and safety of vildagliptin/pioglitazone combination therapy in Korean patients with diabetes (English)

1 reference

9 October 2017

Sun-Woo Kim

1

1 reference

9 October 2017

Sei Hyun Baik

2

1 reference

9 October 2017

Kun Ho Yoon

3

1 reference

9 October 2017

Hyoung Woo Lee

4

1 reference

9 October 2017

Claudia Filozof

5

1 reference

9 October 2017

language of work or name

1 reference

1 November 2010

1 reference

World journal of diabetes

9 October 2017

1 reference

9 October 2017

1

1 reference

9 October 2017

5

1 reference

9 October 2017

153-160

1 reference

Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content

9 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083898

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083898

Diabetes care in the hospital: is there clinical inertia?

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083898

Clinical characteristics of Korean type 2 diabetic patients in 2005.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083898

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083898

Prevalence of diabetes mellitus and population attributable fractions for coronary heart disease and stroke mortality in the WHO South-East Asia and Western Pacific regions.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083898

Pathophysiologic heterogeneity in the development of type 2 diabetes mellitus in Korean subjects

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083898

Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083898

Insulin secretory dysfunction and insulin resistance in the pathogenesis of korean type 2 diabetes mellitus

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083898

Prevalence of obesity in Korean non-insulin-dependent diabetic patients.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3083898

Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT

18 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21537443

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Current status of diabetes management in elderly Koreans with diabetes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21537443

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4239/WJD.V1.I5.153

1 reference

9 October 2017

1 reference

9 October 2017

1 reference